🫀 Can coronary atherosclerosis actually regress? Our new randomized FLOWPROMOTE trial analysis, published TODAY in JAMA Cardiology, shows remarkable coronary plaque regression with intensive LDL-C lowering! Atherosclerosis is not necessarily a one-way process. 📄 JAMA Cardiology: doi.org/10.1001/jamacardio.2… #Atherosclerosis #LDL #Cardiology #CCTA

People who have been in research fields develop a felt sense that most "research" (in almost any field that isn't exactingly technical) is research theater, and many superstar careers enjoy star status not because of a unique connection to the truth but because of a unique connection with an audience. No one really has the time or stature to, from a position of objectivity and trust, bring popular researchers to heel. But it will get increasingly hard to hide from serious critique. The machines can do critique now, at the level of depth and rigor previously only possible for the academically deranged. We're going to have to revise a lot of what we "know" about the world that isn't really knowledge but is actually just received popular consensus - like floating voltages without grounding wires. The grounding wires are coming.

New record for Stack Overflow: <1000 questions posted last month

I believe firmly that AI manuscript review will make science better. Often, low-quality papers slip through and get published, even in high impact journals, because they somehow escaped review by a high-quality human. It's the variance of review quality, not the median, that remains the largest problem with human manuscript review.

Tyler Cowen: 'I am not even sure what to say at this point. We need a radical revaluation of this work, and of the associated policy arguments. More generally, this is only a single step in the story of how AI is going to revise economic science, and indeed past research more generally. As I stress in many of my recent talks, there will be significant gains and losses in status, with the losses often outweighing the gains. I see this as one of those cases.'

😢🫡🤍

Anthropic/OpenAI (and all other Frontier AI companies for that matter) are causing a paradox. They're trying so desperately hard to avoid agents doing "bad things" but in the act of being so cautious and restrictive, are causing the rise in abliterated/uncensored models.

Craig Mello kicking off the nephrology meeting ! @ASNKidney RNA medicines and oligo therapies will be the next generation cures for the kidney patients

If you had an exponential amount of compute you could solve simulate biology exactly and wouldn't need to run any experiments. Some of you will think "of course, but that's an unrealistic assumption" and others will think "no, you need experiments even with that much compute. That's just How It's Done". You would of course need evaluations once you have a solution, but you don't in principle need experiments to find it: Experiments are a way to save compute, dating from a time when it was much more expensive. And I think the presentation is exponential but real systems aren't irreducibly exponential. AlphaFold worked, after all.

The leaked Merck vaccine data @myESMO underscore the challenges of the orchestrated theater of Act 1, company press release -> Act 2 hold data -> Act 3 public report at major meetings. Act 2, the hold phase, builds excitement for the company & discussion but inevitably there are data shared with KOLs and other stakeholders. $MRNA rose 276% (🔼mkt cap $40+B) on press release and fell 18% (🔽$12B) on leak. Seems unclear how this orchestration helps patients or actual research. To the extent there is peer review, it is done by the journals and not the meeting organizers themselves. @adamfeuerstein @matthewherper wsj.com/health/pharma/modern…

The leaked Merck vaccine data @myESMO underscore the challenges of the orchestrated theater of Act 1, company press release -> Act 2 hold data -> Act 3 public report at major meetings. Act 2, the hold phase, builds excitement for the company & discussion but inevitably there are data shared with KOLs and other stakeholders. $MRNA rose 276% (🔼mkt cap $40+B) on press release and fell 18% (🔽$12B) on leak. Seems unclear how this orchestration helps patients or actual research. To the extent there is peer review, it is done by the journals and not the meeting organizers themselves. @adamfeuerstein @matthewherper wsj.com/health/pharma/modern…

Medicine will be the only field in which AI increases cost. Why are doctors allowing AI companies to feed off of the Physician Fee Schedule?

Medicare paying hospitals an extra $137.53 for a chest CT they run thru AIDoc Multi-Triage CT Body software, meanwhile rad actually reading the study only makes about $49. Makes sense. radiologybusiness.com/topics…